한글목차

중환자 치료 진단 세계 시장 규모는 2024년에 13억 3,000만 달러로 평가되었습니다. 2030년까지 연평균 복합 성장률(CAGR)은 5.11%로 예측 기간 중에 크게 성장할 것으로 예측됩니다.

이 시장은 중환자실 환경에서 신속하고 정확한 진단 도구에 대한 요구가 증가함에 따라 빠르게 발전하고 있습니다. 전 세계적으로 만성질환 증가와 고령화로 인해 패혈증, 심장질환, 호흡기질환, 장기부전 등 급성질환의 유병률이 빠르게 증가하고 있습니다. 이러한 증가는 조기 발견과 효율적인 개입이 가능한 첨단 진단의 필요성을 강조하고 있습니다. 예를 들어, 미국의 65세 이상 노인 인구는 2022년 5,800만 명에서 2050년 8,200만 명으로 증가하여 전체 인구의 17%에서 23%로 증가할 것으로 예상되며, 이러한 급격한 인구 통계학적 변화로 인해 중환자 치료 서비스에 대한 수요가 증가하고 있습니다.

시장 성장 촉진요인

중증환자 증가

주요 시장 이슈

고급 진단 비용

주요 시장 동향

분자진단학의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 중환자 치료 진단 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 검사 유형별(유세포분석기, 혈액학 검사, 미생물학 및 감염 검사, 응고 검사, 면역단백질 검사 검사, 루틴 및 특수화학 검사, 기타)
  • 최종사용자별(수술실, 구급실, 집중치료실, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 중환자 치료 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 중환자 치료 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 중환자 치료 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 중환자 치료 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 중환자 치료 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 인수합병(M&A)

제13장 세계의 중환자 치료 진단 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체 치료법 위협

제15장 경쟁 구도

• Neoplas med GmbH
• U.S. Medical Innovations
• Terumo Medical Corp
• Adtec Plasma Technology Co Ltd
• Apyx Medical Corp
• Nordson Corp
• Europlasma NV
• Terraplasma GmbH
• Henniker Plasma
• Smith & Nephew plc

제16장 전략적 제안

제17장 회사 소개 및 면책조항

영문목차

The Global Critical Care Diagnostics Market was valued at USD 1.33 billion in 2024 and is projected to grow significantly during the forecast period with a CAGR of 5.11% through 2030F. This market is rapidly evolving, driven by an increasing need for prompt and precise diagnostic tools in critical care environments. With a global rise in chronic diseases and an aging population, the prevalence of acute conditions such as sepsis, cardiac disorders, respiratory diseases, and organ failure is climbing rapidly. This growth underscores the necessity for advanced diagnostics capable of early detection and efficient intervention. For example, the U.S. population aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, growing from 17% to 23% of the total population, illustrating a sharp demographic shift that intensifies demand for critical care services.

Key Market Drivers

Increasing Incidence of Critical Illnesses

A major driver of growth in the critical care diagnostics market is the rising occurrence of severe medical conditions globally. As populations continue to age and lifestyle patterns evolve, conditions such as sepsis, cardiac and respiratory disorders, and organ failure are becoming more widespread. This has amplified the demand for cutting-edge diagnostic technologies that enable swift and accurate identification of these illnesses. Timely diagnosis is essential in critical care as it facilitates early intervention, thereby improving patient recovery and survival rates. According to the World Health Organization (WHO), approximately 422 million individuals were living with diabetes in 2023, predominantly in low- and middle-income countries. With around 1.5 million annual deaths directly attributed to diabetes, the need for early detection and effective management solutions is particularly pressing in resource-limited settings.

Key Market Challenges

Cost of Advanced Diagnostics

One of the foremost challenges in the critical care diagnostics market is the high cost associated with advanced diagnostic technologies. The growing prevalence of life-threatening health conditions, including sepsis, cardiac and respiratory diseases, and organ failure, is fueling the demand for these innovations. However, the financial burden of acquiring and maintaining such sophisticated diagnostic equipment is considerable. This poses a challenge particularly for healthcare providers operating in resource-constrained regions. Additionally, the aging global population adds further pressure on healthcare systems, making cost-effectiveness a crucial factor in the adoption of diagnostic solutions, especially in public and rural healthcare settings.

Key Market Trends

Advancements in Molecular Diagnostics

Technological progress in molecular diagnostics is shaping a key trend in the critical care diagnostics landscape. This approach analyzes genetic material and other molecular indicators to identify diseases, pathogens, or mutations with high precision. The deeper understanding of genetic factors in disease development has allowed for more accurate and personalized diagnostic techniques. Molecular diagnostics enables detection of illnesses at a cellular level, thereby improving diagnostic accuracy and facilitating tailored treatment plans based on individual genetic profiles. This innovation is redefining diagnostic capabilities in critical care by enhancing both speed and specificity of disease identification.

Key Market Players

• Neoplas med GmbH
• U.S. Medical Innovations
• Terumo Medical Corp
• Adtec Plasma Technology Co Ltd
• Apyx Medical Corp
• Nordson Corp
• Europlasma NV
• Terraplasma GmbH
• Henniker Plasma
• Smith & Nephew plc

Report Scope:

In this report, the Critical Care Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Critical Care Diagnostics Market, Test Type:

• Flow Cytometry
• Hematology Test
• Microbiology and Infectious Test
• Coagulation Test
• Immunoprotein
• Routine and Special Chemistry
• Others

Critical Care Diagnostics Market, End User:

• Operating Room
• Emergency Room
• Intensive Care Unit
• Other

Critical Care Diagnostics Market, By Region:

• North America

United States

Canada

Mexico

• Europe

Germany

United Kingdom

Italy

France

Spain

• Asia Pacific

China

India

Japan

South Korea

Australia

• South America

Brazil

Argentina

Colombia

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Critical Care Diagnostics Market.

Available Customizations:

Critical Care Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Critical Care Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Flow Cytometry, Hematology Test, Microbiology and Infectious Test, Coagulation Test, Immunoprotein, Routine, and Special Chemistry, and Others)
  • 5.2.2. By End User (Operating Room, Emergency Room, Intensive Care Unit, and Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Critical Care Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Critical Care Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Critical Care Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Critical Care Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By End User

7. Europe Critical Care Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Critical Care Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Critical Care Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Critical Care Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By End User
  • 7.3.4. France Critical Care Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Critical Care Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By End User

8. Asia-Pacific Critical Care Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Critical Care Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Critical Care Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Critical Care Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Critical Care Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Critical Care Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By End User

9. South America Critical Care Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Critical Care Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Critical Care Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Critical Care Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Critical Care Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Critical Care Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Critical Care Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Critical Care Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Critical Care Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

• 15.1. Neoplas med GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. U.S. Medical Innovations
• 15.3. Terumo Medical Corp
• 15.4. Adtec Plasma Technology Co Ltd
• 15.5. Apyx Medical Corp
• 15.6. Nordson Corp
• 15.7. Europlasma NV
• 15.8. Terraplasma GmbH
• 15.9. Henniker Plasma
• 15.10. Smith & Nephew plc

16. Strategic Recommendations

17. About Us & Disclaimer